Cantabio Pharmaceuticals is a preclinical stage biotechnology company focused on developing novel therapies for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Their research is centered around reducing the harmful effects of biochemical stress and developing disease-modifying therapeutics. They employ a unique drug discovery approach that integrates therapeutic focus, target family biophysics, and novel drug discovery technologies. Cantabio's pipeline includes small molecule pharmacological chaperones and engineered CNS-penetrant protein therapeutics.

Cantabio Pharmaceuticals, Inc.

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

Cantabio Pharmaceuticals, Inc. awarded major grant from The Michael J. Fox Foundation to develop novel small-molecule aggregation inhibitors of the tau protein for the treatment of Parkinson’s disease https://lnkd.in/djjxwqU2

Cantabio Pharmaceuticals, Inc.’s CEO, Gergely Toth, pitches the company in the finals of the 2021 ATECH Zhongguancun International Frontier Technology Innovation Competition in the Biomedicine category held in Beijing on September 27, 2021.
https://lnkd.in/e6wraueC

Cantabio Pharmaceuticals, Inc.'s CEO, Dr. Toth, is presenting on the therapeutic targeting of the intrinsically disordered state of Tau and alpha-synuclein as a potential treatment approach for #Alzheimers & #Parkinsons at NeuroScience 2021. https://lnkd.in/e69sccjP

Cantabio's drug discovery approach and therapeutic pipeline in #Alzheimers, #Parkinsons and #Diabetes is discussed by Dr. Toth in an interview at Careers in Discovery. https://lnkd.in/eTACFEX

Recent Editorial in Drug Discovery Today, by Cantabio Pharmaceuticals, Inc.'s CEO Dr. Toth with colleagues at UCL School of Pharmacy, argues that crowdfunding is a promising way to generate billions of dollars of much needed new capital for financing R&D of novel diagnostics and therapeutics for Alzheimer's and Parkinson's disease. https://lnkd.in/eQ3tfuj

CTBO

COM:CANTABIO

Cantabio Pharmaceuticals Inc.

Market Cap

563.60K

Beta: -

Volume Today

46

Avg: -

locale

market

industry

website

crunchbase

linkedin

ipo date

peer of

Metrics